Tenet Healthcare Corp (THC) stock
THCNYSEServices-General Medical & Surgical Hospitals, NECFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 13/3039% below fair value
$273.25+2.68 (+0.99%)
Close on Oct 30, 2026Market cap $22.00BP/E 7.9Yield –
Earnings
Tenet Healthcare's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 10, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$5.63B
+6.5% on a year earlier
Adjusted diluted earnings per share, Q3 FY2026
$6.64
$3.70 a year earlier
Latest guidance
Raised
Oct 29, 2026 · 6 items
Quarterly results
Revenue and earnings per share from each of Tenet Healthcare's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 10, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 29, 2026before the open | $5.63B | +6.5% | $12.41 | $6.64 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 23, 2026during market hours | $5.63B | +6.8% | $9.84 | $6.12 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 30, 2026before the open | $5.37B | +2.8% | $8.01 | $4.82 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 11, 2026before the open | $5.53B | +9.0% | $4.22 | $4.70 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 28, 2025before the open | $5.29B | +3.3% | $3.86 | $3.70 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 22, 2025before the open | $5.27B | +3.3% | $3.14 | $4.02 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 29, 2025before the open | $5.22B | -2.7% | $4.27 | $4.36 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 12, 2025before the open | $5.07B | -5.7% | $3.32 | $3.44 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 29, 2024before the open | $5.12B | +1.1% | $4.89 | $2.93 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 24, 2024before the open | $5.10B | +0.4% | $2.64 | $2.31 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 30, 2024before the open | $5.37B | +6.9% | $21.38 | $3.22 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 8, 2024before the open | $5.38B | +7.8% | $2.30 | $2.68 | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 30, 2023during market hours | $5.07B | +5.5% | $0.94 | $1.44 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 31, 2023during market hours | $5.08B | – | $1.15 | $1.44 | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 25, 2023before the open | $5.02B | +5.8% | $1.32 | $1.42 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 9, 2023before the open | $4.99B | +2.8% | $0.92 | $1.96 | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 20, 2022during market hours | $4.80B | -1.9% | $1.16 | $1.44 | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 21, 2022during market hours | – | – | $0.35 | $1.50 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 20, 2022during market hours | $4.75B | – | $1.27 | $1.93 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 7, 2022during market hours | $4.86B | – | $2.30 | $2.70 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 20, 2021during market hours | $4.89B | – | $4.12 | $1.99 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 21, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 20, 2021during market hours | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Jan 11, 2021during market hours | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 20, 2020during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Tenet Healthcare's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Net operating revenuesGAAP | FY2026 | $22.05B – $22.45B | $21.50B – $22.30B | Raised | Oct 29, 2026 |
| Net operating revenues 7GAAP | FY2026 | $21.90B – $22.50B | $21.50B – $22.30B | Raised | Jul 23, 2026 |
| Same-facility system-wide revenuenon-GAAP | FY2026 | +3% – +6% | – | New | Feb 11, 2026 |
| Same-facility system-wide revenuesnon-GAAP | FY2026 | +3% – +6% | – | New | Jul 23, 2026 |
| Same-facility system-wide revenues | FY2026 | +3% – +6% | – | New | Apr 30, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $5.05B – $5.20B | $4.49B – $4.79B | Raised | Oct 29, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $4.83B – $5.03B | $4.49B – $4.79B | Raised | Jul 23, 2026 |
| Diluted income per common shareGAAP | FY2026 | $35.82 – $37.08 | $29.60 – $32.27 | Raised | Oct 29, 2026 |
| Diluted income per common shareGAAP | FY2026 | $34.57 – $36.43 | $29.94 – $32.64 | Raised | Jul 23, 2026 |
| Adjusted diluted earnings per sharenon-GAAP | FY2026 | $22.05 – $23.01 | $16.19 – $18.47 | Raised | Oct 29, 2026 |
| Adjusted diluted earnings per sharenon-GAAP | FY2026 | $20.30 – $21.69 | $16.38 – $18.68 | Raised | Jul 23, 2026 |
| Adjusted free cash flownon-GAAP | FY2026 | $2.83B – $3.13B | $2.94B – $3.29B | Lowered | Oct 29, 2026 |
| Adjusted free cash flownon-GAAP | FY2026 | $2.73B – $3.03B | $2.94B – $3.29B | Raised | Jul 23, 2026 |
| Capital expenditures | FY2026 | $700.00M – $800.00M | – | New | Oct 29, 2026 |
| Capital expendituresGAAP | FY2026 | $700.00M – $800.00M | $700.00M – $800.00M | Reaffirmed | Jul 23, 2026 |
| Capital expendituresGAAP | FY2026 | $700.00M – $800.00M | – | New | Feb 11, 2026 |
| Adjusted admissions | FY2026 | +1% – +2% | – | Reaffirmed | Apr 30, 2026 |
| Adjusted EBITDA marginnon-GAAP | FY2026 | 20.9% – 21.5% | – | New | Apr 30, 2026 |
| Adjusted EBITDA marginnon-GAAP | FY2026 | 20.9% – 21.5% | – | New | Feb 11, 2026 |
| Inpatient admissions | FY2026 | +1% – +2% | – | New | Apr 30, 2026 |
Guidance vs results
The last range Tenet Healthcare gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Adjusted diluted earnings per share | $15.93 – $16.26 | $16.78Σ4Q | Above range |
| FY2025 | EPS (GAAP) | $14.66 – $15.37 | $15.49Σ4Q | Above range |
| FY2025 | Revenue | $21.15B – $21.35B | $21.31BΣ4Q | Within range |
| FY2025 | Revenue growth | +4% – +7% | +3.12%Σ4Q | Below range |
| Q4 FY2024 | Adjusted diluted earnings per share | $2.69 – $3.31 | $3.44 | Above range |
| Q4 FY2024 | EPS (GAAP) | $2.20 – $3.24 | $3.32 | Above range |
| Q4 FY2024 | Revenue | $5.01B – $5.21B | $5.07B | Within range |
| Q3 FY2024 | Adjusted diluted earnings per share | $2.16 – $2.58 | $2.93 | Above range |
| Q3 FY2024 | EPS (GAAP) | $2.01 – $2.47 | $4.89 | Above range |
| Q3 FY2024 | Revenue | $5.00B – $5.10B | $5.12B | Above range |
| Q2 FY2024 | Adjusted diluted earnings per share from continuing operations | $1.58 – $1.98 | $2.31 | Above range |
| Q2 FY2024 | EPS (GAAP) | $1.49 – $1.93 | $2.64 | Above range |
| Q2 FY2024 | Revenue | $4.90B – $5.10B | $5.10B | Above range |
| Q1 FY2024 | Adjusted diluted earnings per share from continuing operations | $1.24 – $1.62 | $3.22 | Above range |
| Q1 FY2024 | EPS (GAAP) | $16.59 – $17.83 | $21.38 | Above range |
| Q1 FY2024 | Revenue | $5.00B – $5.20B | $5.37B | Above range |
| Q4 FY2023 | Adjusted diluted earnings per share from continuing operations | $1.12 – $1.74 | $2.68 | Above range |
| Q4 FY2023 | EPS (GAAP) | $0.83 – $1.64 | $2.30 | Above range |
| Q4 FY2023 | Revenue | $5.13B – $5.33B | $5.38B | Above range |
| Q3 FY2023 | Adjusted diluted earnings per share from continuing operations | $0.94 – $1.28 | $1.44 | Above range |
| Q3 FY2023 | EPS (GAAP) | $0.71 – $1.13 | $0.94 | Within range |
| Q3 FY2023 | Revenue | $4.90B – $5.10B | $5.07B | Within range |
| Q2 FY2023 | Adjusted diluted earnings per share from continuing operations | $1.07 – $1.30 | $1.44 | Above range |
| Q2 FY2023 | EPS (GAAP) | $0.88 – $1.21 | $1.15 | Within range |
| Q2 FY2023 | Revenue | $4.80B – $5.00B | $5.08B | Above range |
| Q1 FY2023 | Adjusted diluted earnings per share from continuing operations | $1.00 – $1.23 | $1.42 | Above range |
| Q1 FY2023 | EPS (GAAP) | $0.82 – $1.14 | $1.32 | Above range |
| Q1 FY2023 | Revenue | $4.70B – $4.90B | $5.02B | Above range |
| Q4 FY2022 | Adjusted diluted earnings per share from continuing operations | $1.00 – $1.54 | $1.96 | Above range |
| Q4 FY2022 | EPS (GAAP) | $0.51 – $1.19 | $0.92 | Within range |
| Q4 FY2022 | Revenue | $4.82B – $5.02B | $4.99B | Within range |
| Q2 FY2022 | Adjusted diluted earnings per share from continuing operations | $1.18 – $1.45 | $1.50 | Above range |
| Q2 FY2022 | EPS (GAAP) | $0.95 – $1.30 | $0.35 | Below range |
| Q1 FY2022 | Adjusted diluted earnings per share from continuing operations | $0.92 – $1.15 | $1.93 | Above range |
| Q1 FY2022 | EPS (GAAP) | $0.69 – $1.01 | $1.27 | Above range |
| Q1 FY2022 | Revenue | $4.60B – $4.80B | $4.75B | Within range |
| Q4 FY2021 | Adjusted diluted earnings per share from continuing operations | $1.29 – $1.52 | $2.70 | Above range |
| Q4 FY2021 | EPS (GAAP) | $0.99 – $1.40 | $2.30 | Above range |
| Q4 FY2021 | Revenue | $4.87B – $5.17B | $4.86B | Below range |
Guidance history
Every forecast Tenet Healthcare put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 29, 2026 | Capital expenditures | FY2026 | $700.00M – $800.00M | New |
| Oct 29, 2026 | Adjusted EBITDA | FY2026 | $5.05B – $5.20B | Raised |
| Oct 29, 2026 | Adjusted diluted earnings per share | FY2026 | $22.05 – $23.01 | Raised |
| Oct 29, 2026 | Diluted income per common share | FY2026 | $35.82 – $37.08 | Raised |
| Oct 29, 2026 | Adjusted free cash flow | FY2026 | $2.83B – $3.13B | Lowered |
| Oct 29, 2026 | Net operating revenues | FY2026 | $22.05B – $22.45B | Raised |
| Jul 23, 2026 | Capital expenditures | FY2026 | $700.00M – $800.00M | Reaffirmed |
| Jul 23, 2026 | Same-facility system-wide revenues | FY2026 | +3% – +6% | New |
| Jul 23, 2026 | Adjusted EBITDA | FY2026 | $4.83B – $5.03B | Raised |
| Jul 23, 2026 | Adjusted diluted earnings per share | FY2026 | $20.30 – $21.69 | Raised |
| Jul 23, 2026 | Diluted income per common share | FY2026 | $34.57 – $36.43 | Raised |
| Jul 23, 2026 | Adjusted free cash flow | FY2026 | $2.73B – $3.03B | Raised |
| Jul 23, 2026 | Net operating revenues 7 | FY2026 | $21.90B – $22.50B | Raised |
| Apr 30, 2026 | Capital expenditures | FY2026 | $700.00M – $800.00M | New |
| Apr 30, 2026 | Same-facility system-wide revenues | FY2026 | +3% – +6% | New |
| Apr 30, 2026 | Adjusted EBITDA | FY2026 | $4.49B – $4.79B | New |
| Apr 30, 2026 | Adjusted diluted earnings per share | FY2026 | $16.38 – $18.68 | New |
| Apr 30, 2026 | Diluted income per common share | FY2026 | $29.94 – $32.64 | New |
| Apr 30, 2026 | Free cash flow | FY2026 | $2.94B – $3.29B | New |
| Apr 30, 2026 | Adjusted free cash flow | FY2026 | $2.50B – $2.80B | Lowered |
| Apr 30, 2026 | Adjusted EBITDA margin | FY2026 | 20.9% – 21.5% | New |
| Apr 30, 2026 | Inpatient admissions | FY2026 | +1% – +2% | New |
| Apr 30, 2026 | Adjusted admissions | FY2026 | +1% – +2% | Reaffirmed |
| Apr 30, 2026 | Net operating revenues | FY2026 | $21.50B – $22.30B | New |
| Feb 11, 2026 | Capital expenditures | FY2026 | $700.00M – $800.00M | New |
| Feb 11, 2026 | Same-facility system-wide revenue | FY2026 | +3% – +6% | New |
| Feb 11, 2026 | Adjusted EBITDA | FY2026 | $4.49B – $4.79B | New |
| Feb 11, 2026 | Adjusted diluted earnings per share | FY2026 | $16.19 – $18.47 | New |
| Feb 11, 2026 | Diluted income per common share | FY2026 | $29.60 – $32.27 | New |
| Feb 11, 2026 | Free cash flow | FY2026 | $2.94B – $3.29B | New |
| Feb 11, 2026 | Adjusted EBITDA margin | FY2026 | 20.9% – 21.5% | New |
| Feb 11, 2026 | Net operating revenues | FY2026 | $21.50B – $22.30B | New |
| Oct 28, 2025 | Capital expenditures | FY2025 | $875.00M – $975.00M | Raised |
| Oct 28, 2025 | Adjusted EBITDA | FY2025 | $4.47B – $4.57B | Raised |
| Oct 28, 2025 | Adjusted diluted earnings per share | FY2025 | $15.93 – $16.26 | Raised |
| Oct 28, 2025 | Diluted income per common share | FY2025 | $14.66 – $15.37 | Raised |
| Oct 28, 2025 | Free cash flow | FY2025 | $2.28B – $2.53B | Raised |
| Oct 28, 2025 | Adjusted free cash flow | FY2025 | $2.43B – $2.63B | Raised |
| Oct 28, 2025 | Adjusted EBITDA margin | FY2025 | 21.1% – 21.4% | Raised |
| Oct 28, 2025 | Net cash provided by operating activities | FY2025 | $3.15B – $3.50B | New |
| Oct 28, 2025 | Net income available to Tenet common stockholders | FY2025 | $1.33B – $1.40B | New |
| Oct 28, 2025 | Adjusted net income | FY2025 | $1.45B – $1.48B | New |
| Oct 28, 2025 | Adjusted net cash provided by operating activities | FY2025 | $3.30B – $3.60B | Raised |
| Oct 28, 2025 | Net operating revenues | FY2025 | $21.15B – $21.35B | New |
| Jul 22, 2025 | Capital expenditures | FY2025 | $725.00M – $825.00M | New |
| Jul 22, 2025 | Adjusted EBITDA (Ambulatory Segment) | FY2025 | $1.99B – $2.05B | Lowered |
| Jul 22, 2025 | Adjusted EBITDA | FY2025 | $4.40B – $4.54B | New |
| Jul 22, 2025 | Adjusted EBITDA (Hospital Segment) | FY2025 | $2.41B – $2.49B | Raised |
| Jul 22, 2025 | Adjusted diluted earnings per share | FY2025 | $15.55 – $16.21 | New |
| Jul 22, 2025 | Diluted income per common share | FY2025 | $14.05 – $15.15 | New |
| Jul 22, 2025 | Adjusted free cash flow | FY2025 | $2.18B – $2.38B | Raised |
| Jul 22, 2025 | Free cash flow | FY2025 | $2.03B – $2.28B | New |
| Jul 22, 2025 | Adjusted EBITDA margin | FY2025 | 21% – 21.4% | New |
| Jul 22, 2025 | Inpatient admissions (Hospital Segment) | FY2025 | +2% – +3% | New |
| Jul 22, 2025 | Adjusted admissions (Hospital Segment) | FY2025 | +1.5% – +2.5% | Lowered |
| Jul 22, 2025 | Same-facility system-wide revenue (Ambulatory Segment) | FY2025 | +4% – +7% | New |
| Jul 22, 2025 | Net operating revenues | FY2025 | $20.95B – $21.25B | New |
| Jul 22, 2025 | Net operating revenues (Ambulatory Segment) | FY2025 | $5.00B – $5.15B | Lowered |
| Jul 22, 2025 | Net operating revenues (Hospital Segment) | FY2025 | $15.95B – $16.10B | Raised |
| Apr 29, 2025 | Capital expenditures | FY2025 | $700.00M – $800.00M | New |
| Apr 29, 2025 | Same-facility system-wide revenue | FY2025 | +3% – +6% | New |
| Apr 29, 2025 | Adjusted EBITDA | FY2025 | $3.98B – $4.18B | New |
| Apr 29, 2025 | Adjusted diluted earnings per share | FY2025 | $11.99 – $13.12 | New |
| Apr 29, 2025 | Diluted income per common share | FY2025 | $11.37 – $12.92 | New |
| Apr 29, 2025 | Free cash flow | FY2025 | $1.80B – $2.05B | New |
| Apr 29, 2025 | Adjusted free cash flow | FY2025 | $1.90B – $2.10B | Raised |
| Apr 29, 2025 | Adjusted EBITDA margin | FY2025 | 19.3% – 19.9% | New |
| Apr 29, 2025 | Inpatient admissions | FY2025 | +2% – +3% | New |
| Apr 29, 2025 | Adjusted admissions | FY2025 | +2% – +3% | Reaffirmed |
| Apr 29, 2025 | Net operating revenues | FY2025 | $20.60B – $21.00B | New |
| Oct 29, 2024 | Capital expenditures | FY2024 | $800.00M – $900.00M | Raised |
| Oct 29, 2024 | Adjusted EBITDA | Q4 FY2024 | $953.00M – $1.05B | New |
| Oct 29, 2024 | Adjusted EBITDA | FY2024 | $3.90B – $4.00B | Raised |
| Oct 29, 2024 | Adjusted diluted earnings per share | Q4 FY2024 | $2.69 – $3.31 | New |
| Oct 29, 2024 | Adjusted diluted earnings per share | FY2024 | $11.12 – $11.73 | Raised |
| Oct 29, 2024 | Diluted income per common share | Q4 FY2024 | $2.20 – $3.24 | New |
| Oct 29, 2024 | Diluted income per common share | FY2024 | $31.56 – $32.58 | Raised |
| Oct 29, 2024 | Free cash flow | FY2024 | $975.00M – $1.23B | Lowered |
| Oct 29, 2024 | Adjusted free cash flow | FY2024 | $1.15B – $1.35B | Raised |
| Oct 29, 2024 | Weighted average diluted common shares | Q4 FY2024 | 96 | New |
| Oct 29, 2024 | Adjusted EBITDA margin | Q4 FY2024 | 19% – 20.2% | New |
| Oct 29, 2024 | Net income available to Tenet common stockholders | Q4 FY2024 | $211.00M – $311.00M | New |
| Oct 29, 2024 | Equity in earnings of unconsolidated affiliates | Q4 FY2024 | $78.00M – $88.00M | Lowered |
| Oct 29, 2024 | Depreciation and amortization | Q4 FY2024 | $195.00M – $215.00M | Raised |
| Oct 29, 2024 | Interest expense | Q4 FY2024 | $197.00M – $207.00M | Narrowed |
| Oct 29, 2024 | Income tax expense | Q4 FY2024 | $84.00M – $114.00M | Lowered |
| Oct 29, 2024 | Net income available to NCI | Q4 FY2024 | $225.00M – $245.00M | Raised |
| Oct 29, 2024 | Adjusted net income | Q4 FY2024 | $258.00M – $318.00M | New |
| Oct 29, 2024 | Weighted average diluted common shares | FY2024 | 98 | New |
| Oct 29, 2024 | Adjusted EBITDA margin | FY2024 | 18.9% – 19.2% | New |
| Oct 29, 2024 | NCI cash distributions | FY2024 | $725.00M – $775.00M | New |
| Oct 29, 2024 | Net income available to Tenet common stockholders | FY2024 | $3.09B – $3.19B | New |
| Oct 29, 2024 | Equity in earnings of unconsolidated affiliates | FY2024 | $260.00M – $270.00M | Lowered |
| Oct 29, 2024 | Depreciation and amortization | FY2024 | $820.00M – $840.00M | Raised |
| Oct 29, 2024 | Interest expense | FY2024 | $820.00M – $830.00M | Lowered |
| Oct 29, 2024 | Income tax expense | FY2024 | $1.19B – $1.22B | Raised |
| Oct 29, 2024 | Net income available to NCI | FY2024 | $835.00M – $855.00M | Lowered |
| Oct 29, 2024 | Net cash provided by operating activities | FY2024 | $1.78B – $2.13B | Raised |
| Oct 29, 2024 | Adjusted net income | FY2024 | $1.09B – $1.15B | New |
| Oct 29, 2024 | Adjusted net cash provided by operating activities | FY2024 | $1.95B – $2.25B | Raised |
| Oct 29, 2024 | Net operating revenues | Q4 FY2024 | $5.01B – $5.21B | New |
| Oct 29, 2024 | Net operating revenues | FY2024 | $20.60B – $20.80B | Lowered |
| Jul 24, 2024 | Capital expenditures | FY2024 | $800.00M – $900.00M | Raised |
| Jul 24, 2024 | Adjusted EBITDA | Q3 FY2024 | $900.00M – $950.00M | New |
| Jul 24, 2024 | Adjusted EBITDA | FY2024 | $3.83B – $3.98B | Raised |
| Jul 24, 2024 | Adjusted diluted earnings per share | Q3 FY2024 | $2.16 – $2.58 | New |
| Jul 24, 2024 | Adjusted diluted earnings per share | FY2024 | $10.41 – $11.12 | Raised |
| Jul 24, 2024 | Diluted income per common share | Q3 FY2024 | $2.01 – $2.47 | New |
| Jul 24, 2024 | Diluted income per common share | FY2024 | $28.83 – $29.90 | Raised |
| Jul 24, 2024 | Free cash flow | FY2024 | $1.10B – $1.35B | Raised |
| Jul 24, 2024 | Net operating revenues | Q3 FY2024 | $5.00B – $5.10B | New |
| Jul 24, 2024 | Net operating revenues | FY2024 | $20.60B – $21.00B | Raised |
| Apr 30, 2024 | Capital expenditures | FY2024 | $775.00M – $875.00M | New |
| Apr 30, 2024 | Adjusted EBITDA | Q2 FY2024 | $835.00M – $885.00M | New |
| Apr 30, 2024 | Adjusted EBITDA | FY2024 | $3.50B – $3.70B | Raised |
| Apr 30, 2024 | Adjusted diluted earnings per share from continuing operations | Q2 FY2024 | $1.58 – $1.98 | New |
| Apr 30, 2024 | Adjusted diluted earnings per share from continuing operations | FY2024 | $8.37 – $9.41 | Raised |
| Apr 30, 2024 | Diluted income per common share from continuing operations | Q2 FY2024 | $1.49 – $1.93 | New |
| Apr 30, 2024 | Diluted income per common share from continuing operations | FY2024 | $25.96 – $27.35 | Raised |
| Apr 30, 2024 | Free cash flow – continuing operations | FY2024 | $950.00M – $1.20B | Raised |
| Apr 30, 2024 | Net operating revenues | Q2 FY2024 | $4.90B – $5.10B | New |
| Apr 30, 2024 | Net operating revenues | FY2024 | $20.00B – $20.40B | Raised |
| Feb 8, 2024 | Capital expenditures | FY2024 | $775.00M – $875.00M | New |
| Feb 8, 2024 | Adjusted EBITDA | Q1 FY2024 | $800.00M – $850.00M | New |
| Feb 8, 2024 | Adjusted EBITDA | FY2024 | $3.29B – $3.49B | New |
| Feb 8, 2024 | Adjusted diluted earnings per share from continuing operations | Q1 FY2024 | $1.24 – $1.62 | New |
| Feb 8, 2024 | Adjusted diluted earnings per share from continuing operations | FY2024 | $5.76 – $6.90 | New |
| Feb 8, 2024 | Diluted income per common share from continuing operations | Q1 FY2024 | $16.59 – $17.83 | New |
| Feb 8, 2024 | Diluted income per common share from continuing operations | FY2024 | $20.69 – $23.02 | New |
| Feb 8, 2024 | Free cash flow – continuing operations | FY2024 | $875.00M – $1.13B | New |
| Feb 8, 2024 | Net operating revenues | Q1 FY2024 | $5.00B – $5.20B | New |
| Feb 8, 2024 | Net operating revenues | FY2024 | $19.90B – $20.30B | New |
| Oct 30, 2023 | Capital expenditures | FY2023 | $675.00M – $725.00M | Reaffirmed |
| Oct 30, 2023 | Adjusted EBITDA | Q4 FY2023 | $836.00M – $936.00M | New |
| Oct 30, 2023 | Adjusted EBITDA | FY2023 | $3.37B – $3.47B | Raised |
| Oct 30, 2023 | Adjusted diluted earnings per share from continuing operations | Q4 FY2023 | $1.12 – $1.74 | New |
| Oct 30, 2023 | Adjusted diluted earnings per share from continuing operations | FY2023 | $5.43 – $6.05 | Raised |
| Oct 30, 2023 | Diluted income per common share from continuing operations | Q4 FY2023 | $0.83 – $1.64 | New |
| Oct 30, 2023 | Diluted income per common share from continuing operations | FY2023 | $4.25 – $5.06 | Narrowed |
| Oct 30, 2023 | Free cash flow | FY2023 | $1.13B – $1.35B | Raised |
| Oct 30, 2023 | Net operating revenues | Q4 FY2023 | $5.13B – $5.33B | New |
| Oct 30, 2023 | Net operating revenues | FY2023 | $20.30B – $20.50B | Raised |
| Jul 31, 2023 | Capital expenditures | FY2023 | $675.00M – $725.00M | Raised |
| Jul 31, 2023 | Adjusted EBITDA | Q3 FY2023 | $775.00M – $825.00M | New |
| Jul 31, 2023 | Adjusted EBITDA | FY2023 | $3.31B – $3.46B | Raised |
| Jul 31, 2023 | Adjusted diluted earnings per share from continuing operations | Q3 FY2023 | $0.94 – $1.28 | New |
| Jul 31, 2023 | Adjusted diluted earnings per share from continuing operations | FY2023 | $5.18 – $6.03 | Narrowed |
| Jul 31, 2023 | Diluted income per common share from continuing operations | Q3 FY2023 | $0.71 – $1.13 | New |
| Jul 31, 2023 | Diluted income per common share from continuing operations | FY2023 | $4.19 – $5.48 | Lowered |
| Jul 31, 2023 | Free cash flow | FY2023 | $1.10B – $1.35B | Reaffirmed |
| Jul 31, 2023 | Net operating revenues | Q3 FY2023 | $4.90B – $5.10B | New |
| Jul 31, 2023 | Net operating revenues | FY2023 | $20.10B – $20.50B | Raised |
| Apr 25, 2023 | Capital expenditures | FY2023 | $625.00M – $675.00M | New |
| Apr 25, 2023 | Adjusted EBITDA | Q2 FY2023 | $765.00M – $815.00M | New |
| Apr 25, 2023 | Adjusted EBITDA | FY2023 | $3.21B – $3.41B | New |
| Apr 25, 2023 | Adjusted diluted earnings per share from continuing operations | Q2 FY2023 | $1.07 – $1.30 | New |
| Apr 25, 2023 | Adjusted diluted earnings per share from continuing operations | FY2023 | $4.92 – $6.09 | Raised |
| Apr 25, 2023 | Diluted income per common share from continuing operations | Q2 FY2023 | $0.88 – $1.21 | New |
| Apr 25, 2023 | Diluted income per common share from continuing operations | FY2023 | $4.24 – $5.79 | Raised |
| Apr 25, 2023 | Free cash flow | FY2023 | $1.10B – $1.35B | Raised |
| Apr 25, 2023 | Net operating revenues | Q2 FY2023 | $4.80B – $5.00B | New |
| Apr 25, 2023 | Net operating revenues | FY2023 | $19.80B – $20.20B | Raised |
| Feb 9, 2023 | Capital expenditures | FY2023 | $625.00M – $675.00M | New |
| Feb 9, 2023 | Adjusted EBITDA | Q1 FY2023 | $750.00M – $800.00M | New |
| Feb 9, 2023 | Adjusted diluted earnings per share from continuing operations | Q1 FY2023 | $1.00 – $1.23 | New |
| Feb 9, 2023 | Adjusted diluted earnings per share from continuing operations | FY2023 | $4.68 – $5.85 | New |
| Feb 9, 2023 | Diluted income per common share from continuing operations | Q1 FY2023 | $0.82 – $1.14 | New |
| Feb 9, 2023 | Diluted income per common share from continuing operations | FY2023 | $3.89 – $5.43 | New |
| Feb 9, 2023 | Free cash flow | FY2023 | $1.08B – $1.33B | New |
| Feb 9, 2023 | Net operating revenues | Q1 FY2023 | $4.70B – $4.90B | New |
| Feb 9, 2023 | Net operating revenues | FY2023 | $19.70B – $20.10B | New |
| Oct 20, 2022 | Capital expenditures | FY2022 | $725.00M – $775.00M | Reaffirmed |
| Oct 20, 2022 | Adjusted EBITDA | Q4 FY2022 | $803.00M – $903.00M | New |
| Oct 20, 2022 | Adjusted EBITDA | FY2022 | $3.38B – $3.48B | Lowered |
| Oct 20, 2022 | Adjusted diluted earnings per share from continuing operations | Q4 FY2022 | $1.00 – $1.54 | New |
| Oct 20, 2022 | Adjusted diluted earnings per share from continuing operations | FY2022 | $5.88 – $6.42 | Narrowed |
| Oct 20, 2022 | Diluted income per common share from continuing operations | Q4 FY2022 | $0.51 – $1.19 | New |
| Oct 20, 2022 | Diluted income per common share from continuing operations | FY2022 | $3.34 – $4.02 | Lowered |
| Oct 20, 2022 | Free cash flow | FY2022 | $300.00M – $525.00M | Lowered |
| Oct 20, 2022 | Net operating revenues | Q4 FY2022 | $4.82B – $5.02B | New |
| Oct 20, 2022 | Net operating revenues | FY2022 | $19.00B – $19.20B | Lowered |
| Apr 20, 2022 | Capital expenditures | FY2022 | $725.00M – $775.00M | Reaffirmed |
| Apr 20, 2022 | Adjusted EBITDA | Q2 FY2022 | $800.00M – $850.00M | New |
| Apr 20, 2022 | Adjusted EBITDA | FY2022 | $3.38B – $3.58B | Reaffirmed |
| Apr 20, 2022 | Adjusted diluted earnings per share from continuing operations | Q2 FY2022 | $1.18 – $1.45 | New |
| Apr 20, 2022 | Adjusted diluted earnings per share from continuing operations | FY2022 | $5.86 – $7.03 | Lowered |
| Apr 20, 2022 | Diluted income per common share from continuing operations | Q2 FY2022 | $0.95 – $1.30 | New |
| Apr 20, 2022 | Diluted income per common share from continuing operations | FY2022 | $4.47 – $6.05 | Lowered |
| Apr 20, 2022 | Free cash flow | FY2022 | $425.00M – $675.00M | Reaffirmed |
| Apr 20, 2022 | Net operating revenues | Q2 FY2022 | $4.80B – $5.00B | New |
| Apr 20, 2022 | Net operating revenues | FY2022 | $19.50B – $19.90B | Reaffirmed |
| Feb 7, 2022 | Capital expenditures | FY2022 | $725.00M – $775.00M | New |
| Feb 7, 2022 | Adjusted EBITDA | Q1 FY2022 | $725.00M – $775.00M | New |
| Feb 7, 2022 | Adjusted EBITDA | FY2022 | $3.38B – $3.58B | New |
| Feb 7, 2022 | Adjusted diluted earnings per share from continuing operations | Q1 FY2022 | $0.92 – $1.15 | New |
| Feb 7, 2022 | Adjusted diluted earnings per share from continuing operations | FY2022 | $5.86 – $7.05 | New |
| Feb 7, 2022 | Diluted income per common share from continuing operations | Q1 FY2022 | $0.69 – $1.01 | New |
| Feb 7, 2022 | Diluted income per common share from continuing operations | FY2022 | $4.56 – $6.16 | New |
| Feb 7, 2022 | Free cash flow | FY2022 | $425.00M – $675.00M | New |
| Feb 7, 2022 | Net operating revenues | Q1 FY2022 | $4.60B – $4.80B | New |
| Feb 7, 2022 | Net operating revenues | FY2022 | $19.50B – $19.90B | New |
| Oct 20, 2021 | Capital expenditures | FY2021 | $675.00M – $725.00M | New |
| Oct 20, 2021 | Adjusted EBITDA | Q4 FY2021 | $809.00M – $859.00M | New |
| Oct 20, 2021 | Adjusted EBITDA | FY2021 | $3.28B – $3.33B | New |
| Oct 20, 2021 | Adjusted diluted earnings per share from continuing operations | Q4 FY2021 | $1.29 – $1.52 | New |
| Oct 20, 2021 | Adjusted diluted earnings per share from continuing operations | FY2021 | $6.15 – $6.38 | New |
| Oct 20, 2021 | Diluted income per common share from continuing operations | Q4 FY2021 | $0.99 – $1.40 | New |
| Oct 20, 2021 | Diluted income per common share from continuing operations | FY2021 | $7.09 – $7.50 | New |
| Oct 20, 2021 | Adjusted free cash flow | FY2021 | $650.00M – $850.00M | New |
| Oct 20, 2021 | Net operating revenues | Q4 FY2021 | $4.87B – $5.17B | New |
| Oct 20, 2021 | Net operating revenues | FY2021 | $19.50B – $19.80B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Tenet Healthcare filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Results
- Results
- Results
- Update
- Update
- Results
- Results
- Results
- Results
- Results
- Update